Flag of the European Union EU Clinical Trials Register Help

Clinical trials for LINE

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44338   clinical trials with a EudraCT protocol, of which   7368   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    4,836 result(s) found for: LINE. Displaying page 1 of 242.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2018-000347-60 Sponsor Protocol Number: TTD-18-01 Start Date*: 2018-08-08
    Sponsor Name:Grupo de Tratamiento de los Tumores Digestivos (TTD)
    Full Title: Phase III randomized sequential open-label study to evaluate the efficacy of FOLFOX + panitumumab followed by FOLFIRI + bevacizumab (Sequence 1) versus FOLFOX + bevacizumab followed by FOLFIRI + pa...
    Medical condition: metastatic colorectal cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10052362 Metastatic colorectal cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing) PT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2009-014041-81 Sponsor Protocol Number: 2906 Start Date*: 2009-11-13
    Sponsor Name:GOIM GRUPPO ONCOLOGICO MERIDIONALE
    Full Title: Optimal strategy in K-ras wild type metastatic colorectal cancer patients: cetuximab plus FOLFIRI followed by FOLFOX+/- cetuximab (GOIM multicenter program)
    Medical condition: k-ras wild type metastatic colorectal cancer patients
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2012-003065-17 Sponsor Protocol Number: CRAD001Y24135 Start Date*: 2013-05-16
    Sponsor Name:Novartis Pharma Services AG
    Full Title: An open-label, phase II, single-arm study of everolimus in combination with letrozole in the treatment of postmenopausal women with estrogen receptor positive HER2 negative metastatic or locally ad...
    Medical condition: Estrogen receptor positive metastatic breast cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10070577 Oestrogen receptor positive breast cancer PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: GB (GB - no longer in EU/EEA) ES (Completed) FR (Completed) NL (Completed) PT (Completed) HU (Completed)
    Trial results: View results
    EudraCT Number: 2008-000756-27 Sponsor Protocol Number: VUB08001 Start Date*: 2008-06-23
    Sponsor Name:UZ Brussel
    Full Title: Activity of sunitinib in esophageal cancer, melanoma and sarcoma.
    Medical condition: Patients with advanced esophageal cancer, melanoma and sarcoma.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2005-003148-79 Sponsor Protocol Number: 08/05 Start Date*: 2006-03-21
    Sponsor Name:Wirral Hospitals NHS Trust
    Full Title: Role of antibiotic line locks in the prevention of tunnelled haemodialysis catheter infection: a double blind randomised controlled trial.
    Medical condition: Tunnelled haemodialysis catheter related infection. These infections are common (approximately 2-7 infections per 1000 catheter days) in patients on haemodialysis; we aim to assess the efficacy of ...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2017-003242-25 Sponsor Protocol Number: GITuD-20172019 Start Date*: 2018-03-02
    Sponsor Name:ASOCIACION GITuD
    Full Title: Analysis of 2nd line panitumumab + FOLFIRI efficacy in wild type RAS converted subjects from initially mutated RAS subjects with metastatic colorectal cancer treated in 1st line with standard FOLFO...
    Medical condition: Wild-type RAS metastatic colorectal cancer (mCRC)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10052358 Colorectal cancer metastatic PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2015-002142-31 Sponsor Protocol Number: 547-SSE-301 Start Date*: 2016-11-16
    Sponsor Name:Sage Therapeutics
    Full Title: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF SAGE-547 INJECTION IN THE TREATMENT OF SUBJECTS WITH SUPER-REFRACTORY STATUS EPILEPTICUS
    Medical condition: SUPER-REFRACTORY STATUS EPILEPTICUS (SRSE)
    Disease: Version SOC Term Classification Code Term Level
    19.1 10029205 - Nervous system disorders 10041962 Status epilepticus PT
    Population Age: Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) BE (Completed) SE (Completed) DK (Completed) ES (Completed) NL (Completed) FI (Completed) HU (Completed) AT (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2013-001322-26 Sponsor Protocol Number: SOV01 Start Date*: 2013-12-02
    Sponsor Name:SOTIO a.s.
    Full Title: A randomized, open-label, three-arm, multi-center Phase II clinical trial evaluating effect of addition of DCVAC/OvCa to first line standard chemotherapy (carboplatin and paclitaxel) in women with ...
    Medical condition: epithelial ovarian carcinoma
    Disease: Version SOC Term Classification Code Term Level
    17.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061328 Ovarian epithelial cancer PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: DE (Completed) CZ (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2008-005011-18 Sponsor Protocol Number: 09072008-13772 Start Date*: 2008-11-05
    Sponsor Name:Deutsche Krebsgesellschaft e.V.
    Full Title: A phase III randomized sequential open-label study to evaluate the efficacy and safety of sorafenib followed by sunitinib versus sunitinib followed by sorafenib in the treatment of first-line advan...
    Medical condition: First-line advanced / metastatic renal cell carcinoma
    Disease: Version SOC Term Classification Code Term Level
    9.1 10050513 Metastatic renal cell carcinoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed) DE (Completed) AT (Completed)
    Trial results: View results
    EudraCT Number: 2008-006713-25 Sponsor Protocol Number: ASSENTE Start Date*: 2008-09-23
    Sponsor Name:OSPEDALE MAGGIORE DI MILANO (IRCCS)
    Full Title: A SINGLE-ARM PILOT STUDY WITH LOW-DOSE RITUXIMAB PLUS STANDARD ORAL PREDNISONE IN IDIOPATHIC AUTOIMMUNE HEMOLYTIC ANEMIA
    Medical condition: ANEMIE EMOLITICHE AUTOIMMUNI IDIOPATICHE
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2007-002886-11 Sponsor Protocol Number: BEBYP Start Date*: 2008-01-14
    Sponsor Name:G.O.N.O. - GRUPPO ONCOLOGICO NORD OVEST
    Full Title: AN OPEN-LABEL, MULTICENTER, RANDOMIZED PHASE III STUDY OF SECOND-LINE CHEMOTHERAPY WITH OR WITHOUT BEVACIZUMAB IN METASTATIC COLORECTAL CANCER PATIENTS WHO HAVE RECEIVED FIRST-LINE CHEMOTHERAPY PLU...
    Medical condition: METASTATIC COLORECTAL CANCER PATIENTS
    Disease: Version SOC Term Classification Code Term Level
    9.1 10052358 Colorectal cancer metastatic LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2007-005021-30 Sponsor Protocol Number: FARM5P8YFC Start Date*: 2007-10-31
    Sponsor Name:REGIONE LOMBARDIA - DIREZIONE GENERALE SANITA'
    Full Title: TOP TRIAL. A RANDOMISED PHASE III CLINICAL TRIAL OF TRASTUZUMAB (HERCEPTIN) OPTIMIZATION IN PATIENTS WITH LOCALLY ADVANCED AND/OR METASTATIC BREAST CANCER OVEREXPRESSING HER2 AFTER A FIRST LINE CHE...
    Medical condition: Women with locally advanced or metastatic breast cancer over expressing HER2 who have been previously treated with a first line chemotherapy plus trastuzumab.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10006279 Breast neoplasm LLT
    Population Age: Adults Gender: Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2012-002556-17 Sponsor Protocol Number: SAKK22/10/UC-0140/1207 Start Date*: 2013-02-04
    Sponsor Name:UNICANCER
    Full Title: A randomized phase II trial of pertuzumab in combination with trastuzumab with or without chemotherapy, both followed by T-DM1 in case of progression, in patients with HER2-positive metastatic brea...
    Medical condition: HER2-positive metastatic breast cancer
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006187 Breast cancer PT
    Population Age: Gender: Female
    Trial protocol: FR (Completed) DE (Completed) NL (Completed)
    Trial results: View results
    EudraCT Number: 2020-003908-14 Sponsor Protocol Number: M-2020-371 Start Date*: 2021-07-07
    Sponsor Name:Miltenyi Biomedicine GmbH
    Full Title: A pivotal Phase II randomised, multi-centre, open-label study to evaluate the efficacy and safety of MB-CART2019.1 compared to standard of care therapy in participants with relapsed/refractory diff...
    Medical condition: Relapsed/refractory diffuse large B cell lymphoma (R-R DLBCL)
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10003903 B-cell lymphoma refractory PT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10003902 B-cell lymphoma recurrent PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Trial now transitioned) LT (Trial now transitioned) AT (Trial now transitioned) NL (Trial now transitioned) BE (Trial now transitioned) DE (Trial now transitioned) IT (Trial now transitioned) ES (Ongoing) HU (Trial now transitioned) CZ (Trial now transitioned) PL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2012-001472-10 Sponsor Protocol Number: INCB24360-210 Start Date*: 2012-10-19
    Sponsor Name:Incyte Corporation
    Full Title: A RANDOMIZED, OPEN-LABEL, PHASE 2 STUDY OF THE IDO INHIBITOR INCB024360 VERSUS TAMOXIFEN FOR SUBJECTS WITH BIOCHEMICAL-RECURRENT-ONLY EPITHELIAL OVARIAN CANCER, PRIMARY PERITONEAL CARCINOMA, OR FAL...
    Medical condition: BIOCHEMICAL-RECURRENT-ONLY EPITHELIAL OVARIAN CANCER, PRIMARY PERITONEAL CARCINOMA, OR FALLOPIAN TUBE CANCER FOLLOWING COMPLETE REMISSION WITH FIRST-LINE CHEMOTHERAPY
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2016-005238-31 Sponsor Protocol Number: TENEC Start Date*: 2017-03-13
    Sponsor Name:ISTITUTO NAZIONALE TUMORI - IRCCS FONDAZIONE PASCALE
    Full Title: A Phase II Single Arm Trial Evaluating the Efficacy and Safety of Temozolomide for Second-Line Treatment of Neuroendocrine Carcinomas Progressing after First-Line Platinum- based Therapy
    Medical condition: Neuroendocrine Carcinomas
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10057270 Neuroendocrine carcinoma PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10057270 Neuroendocrine carcinoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2017-004519-38 Sponsor Protocol Number: GEMCAD-17-01 Start Date*: 2018-07-04
    Sponsor Name:Grupo Español Multidisciplinar en Cáncer Digestivo (GEMCAD
    Full Title: Randomized phase II study to evaluate the efficacy of second-line FOLFIRI + panitumumab in subjects with wild type RAS metastatic colorectal cancer who have received FOLFOX + panitumumab in first-line
    Medical condition: Subjects treated in first-line with panitumumab and FOLFOX and having at least achieved stable disease with wild type RAS metastatic Colorectal Cancer confirmed in liquid biopsies before starting s...
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10052362 Metastatic colorectal cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2016-003502-13 Sponsor Protocol Number: Ca.So. Start Date*: 2018-01-19
    Sponsor Name:AOU DI BOLOGNA POLICLINICO S.ORSOLA-MALPIGHI
    Full Title: A multicenter, randomized, open-label phase 3 study of two anti-angiogenic strategies in advanced hepatocellular carcinoma patients with cross-over at first-line failure: metronomic Capecitabine/So...
    Medical condition: advanced hepatocellular carcinoma
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10024662 Liver cell carcinoma non-resectable LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2017-003780-35 Sponsor Protocol Number: AIO-TRK-0221 Start Date*: 2019-04-01
    Sponsor Name:AIO-Studien-gGmbH
    Full Title: Randomized phase II, open-label efficacy and safety study of second-line durvalumab plus tremelimumab versus platinum-based chemotherapy alone in patients with NSCLC and first-line checkpoint-inhib...
    Medical condition: Non-small cell lung cancer stage IV
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10029664 Non-small cell neoplasms malignant of the respiratory tract cell type specified HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2014-003698-41 Sponsor Protocol Number: MK-3475-048 Start Date*: 2015-02-19
    Sponsor Name:Merck Sharp & Dohme Corp., a Subsidiary of Merck & Co. Inc.
    Full Title: A Phase 3 Clinical Trial of Pembrolizumab (MK-3475) in First Line Treatment of Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma.
    Medical condition: Recurrent/metastatic head and neck squamous cell carcinoma.
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10071540 Head and neck cancer metastatic PT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10060121 Squamous cell carcinoma of head and neck PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10067821 Head and neck cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) EE (Completed) LV (Completed) DK (Completed) FI (Completed) AT (Completed) CZ (Completed) NL (Completed) HU (Completed) ES (Completed) RO (Ongoing) GR (Completed) DE (Completed) IT (Completed) GB (GB - no longer in EU/EEA) PL (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Tue May 27 20:41:18 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA